merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly's vials are FDA-approved and offer a safer alternative to compounded drugs.</answer>
<question_number>2</question_number>
<answer>LillyDirect allows patients to obtain prescriptions and purchase vials directly from Lilly, bypassing telehealth companies.</answer>
<question_number>3</question_number>
<answer>Compounded drugs are subject to less oversight and may not be as safe or effective as FDA-approved medications.</answer>
<question_number>4</question_number>
<answer>By offering a cheaper alternative, Lilly aims to attract patients who are currently using compounded drugs or cannot afford the pens.</answer>
<question_number>5</question_number>
<answer>The FDA's shortage list allows compounding pharmacies to legally produce alternative versions of medications in short supply.</answer>
<question_number>6</question_number>
<answer>Eli Lilly's direct-to-consumer sales strategy, bypassing insurance coverage, reflects a growing trend in the pharmaceutical industry.</answer>
<question_number>7</question_number>
<answer>Medicare's refusal to cover weight-loss medications could lead to more patients seeking out cheaper alternatives, potentially increasing the use of Zepbound vials.</answer>
<question_number>8</question_number>
<answer>The article suggests that patients may perceive Lilly's FDA-approved vials as a safer option compared to compounded tirzepatide.</answer>
<question_number>9</question_number>
<answer>Tirzepatide is listed on the FDA's shortage list.</answer>
<question_number>10</question_number>
<answer>Dr. Mackey suggests that Lilly is using lower pricing to regain market share from compounding pharmacies.</answer>
